Biodlink

Acquired

Empowering pharmaceutical innovation, improving quality of life, safeguarding human health

Suzhou, China · Founded 2010 · $102.0M raised

Headquarters
Suzhou
Founded
2010
Business Model
B2B
Total Funding
$102.0M
Last Round
$102.0M Series BJan 2018
Rounds
1
Acquisition Date
Jan 2026

About

BioDlink is a biologics CDMO that provides one-stop services from R&D and process development through clinical trials, regulatory submission, and commercial GMP manufacturing. Based in Suzhou Industrial Park, the company operates a large-scale GMP production base with more than 20,000 L of monoclonal antibody drug substance capacity and integrated ADC platforms covering monoclonal antibodies, drug substance, and drug product. Established in 2010 and listed on the Hong Kong Stock Exchange in November 2019, BioDlink serves global pharmaceutical clients under quality systems aligned with FDA, EMA, and NMPA standards.

Summary

Biodlink is a Biotech company based in Suzhou, China, founded in 2010. It has raised $102.0M in total across 1 round, most recently a $102.0M Series B round in Jan 2018. Investors include Chengwei Ventures.

Tech & App Stack

Funding History

AcquisitionJan 2026

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Biodlink on Indexed.vc
<a href="https://indexed.vc/companies/biodlink"><img src="https://indexed.vc/api/badge/company/biodlink" alt="Biodlink on Indexed.vc" width="260" height="76" /></a>